Infinity Pharmaceuticals Added to Russell 2000(r) Index

* Reuters is not responsible for the content in this press release.

Mon Jun 29, 2009 6:30am EDT 

CAMBRIDGE, Mass., June 29, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals,
Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company,
today announced that it was added to the Russell 2000(r) Index when Russell
Investments reconstituted its comprehensive set of U.S. and global equity
indexes on June 26, 2009. The Russell 2000, which is a subset of the Russell
3000(r) Index, measures the performance of the small-cap segment of U.S.
equities. Membership in the Russell 2000 is reevaluated annually.

About Russell Indexes

Annual reconstitution of Russell's U.S. indexes captures the 4,000 largest U.S.
stocks as of the end of May, ranking them by total market capitalization.
Membership in the Russell 2000 also means automatic inclusion in the appropriate
growth and value style indexes. Russell determines membership for its equity
indexes primarily by objective, market-capitalization rankings and style
attributes. Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for both passive and
active investment strategies. An industry-leading $4 trillion in assets
currently are benchmarked to the Russell indexes. These investment tools
originated from Russell's multi-manager investment business in the early 1980s
when the company saw the need for a more objective, market-driven set of
benchmarks in order to evaluate outside investment managers.

About Infinity Pharmaceuticals, Inc.

Infinity is an innovative cancer drug discovery and development company seeking
to discover, develop, and deliver to patients best-in-class medicines for the
treatment of cancer and related conditions. Infinity combines proven scientific
expertise with a passion for developing novel small molecule drugs that target
emerging cancer pathways. Infinity's two most advanced programs in Hsp90
chaperone inhibition and Hedgehog signaling pathway inhibition are evidence of
its innovative approach to oncology drug discovery and development. For more
information on Infinity, please refer to the company's website at
http://www.infi.com.

-0-
CONTACT:  Infinity Pharmaceuticals, Inc.
          Monique Allaire
          617-453-1105
          Monique.Allaire@infi.com 
          http://www.infi.com
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.